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Abstract
Background: Risk adjustment is essential for valid comparison of patients’ health outcomes or performances of
health care providers. Several risk adjustment methods for liver diseases are commonly used but the optimal approach
is unknown. This study aimed to compare the common risk adjustment methods for predicting in-hospital mortality in
cirrhosis patients using electronic medical record (EMR) data.
Methods: The sample was derived from Beijing YouAn hospital between 2010 and 2014. Previously validated EMR
extraction methods were applied to define liver disease conditions, Charlson comorbidity index (CCI), Elixhauser
comorbidity index (ECI), Child-Turcotte-Pugh (CTP), model for end-stage liver disease (MELD), MELD sodium
(MELDNa), and five-variable MELD (5vMELD). The performance of the common risk adjustment models as well as
models combining disease severity and comorbidity indexes for predicting in-hospital mortality was compared
using c-statistic.
Results: Of 11,121 cirrhotic patients, 69.9% were males and 15.8% age 65 or older. The c-statistics across compared
models ranged from 0.785 to 0.887. All models significantly outperformed the baseline model with age, sex, and
admission status (c-statistic: 0.628). The c-statistics for the CCI, ECI, MELDNa, and CTP were 0.808, 0.825, 0.849, and 0.851,
respectively. The c-statistic was 0.887 for combination of CTP and ECI, and 0.882 for combination of MELDNa
score and ECI.
Conclusions: The liver disease severity indexes (i.e., CTP and MELDNa score) outperformed the CCI and ECI for
predicting in-hospital mortality among cirrhosis patients using Chinese EMRs. Combining liver disease severity
and comorbidities indexes could improve the discrimination power of predicting in-hospital mortality.
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Background
Risk adjustment methods have increasingly been used
for a large range of researches, such as health outcomes
studies and health care provider performance assess-
ment. In the past few decades, numerous risk adjust-
ment models have been developed for both general
medical inpatients as well as disease-specific inpatients,
including disease groupers, disease severity indexes, and
comorbidity indexes [1]. For liver disease patients, four
risk adjustment instruments are commonly used to pre-
dict in-hospital mortality: Charlson comorbidity index
(CCI) [2], Elixhauser comorbidity index (ECI) [3], Child-
Turcotte-Pugh (CTP) [4, 5], and model for end-stage
liver disease (MELD) [6, 7].
CCI was originally developed based on medical charts
to estimate 1-year mortality of patients with breast
cancer and was validated in another 10-year follow-up
cohort [3]. Since then, the index has been most widely
used for risk adjustment [8, 9]. In 1998 Elixhauser et al.
introduced a new comorbidity algorithm based on
United States administrative health data to define the 31
conditions for predicting health outcomes including in-
hospital mortality, hospital cost and length of stay [3].
Liver disease studies have shown that ECI performed
better than CCI in administrative health data [9–12].
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Hepatologists use CTP or MELD frequently to predict
short-term prognoses or outcomes such as in-hospital
mortality, post-surgery mortality or procedure related
complications in patients with chronic liver diseases
given both instruments are readily applicable at bedside.
CTP contains five clinical measures and could be used
either as CTP classifications (3 classes for 10 levels of risk)
or as a summary score. CTP included two subjective mea-
sures (degree of ascites and encephalopathy) which lead to
the issue of inter-rater variation. MELD score, on the
other hand, does not employ any subjective measure and
includes three laboratory test results instead. MELD was
initially used to evaluate the risk of death after transjugu-
lar intrahepatic portosystemic shunt for patients with
cirrhosis, and later used for predicting mortality before or
after liver transplantation for patients with end-stage liver
diseases [6, 7]. MELD score is regarded more objective and
reproducible than CTP and replaced CTP in organ alloca-
tion systems such as United Network for Organ Sharing
for patients waiting for liver transplantation [13, 14].
The choice of these four risk adjustment methods
often depends on data availability. CCI and ECI can be
constructed using administrative health data [9, 10, 12,
15–19], while MELD and CTP are used in primary clinical
data [20–24]. As a result, performance of these risk adjust-
ment models has not been compared on the same liver
patient population. It remains unclear what is the best risk
adjustment approach for liver disease.
As a result of rapid development and wide use of elec-
tronic medical record (EMR) in China in recent years,
an enormous amount of EMR data is being collected
[25, 26]. Additionally, liver diseases, including viral hepa-
titis, cirrhosis, and primary liver cancer (PLC), are highly
prevalent in China [27]. About 97 million people are
hepatitis B carriers [28]; at least 20 million patients have
chronic hepatitis B with or without cirrhosis and/or PLC
[27, 28]. Between 2006 and 2010, about 1.2% of inpa-
tients in general hospitals in Beijing were admitted due
to cirrhosis (mainly hepatitis cirrhosis) [29]. Therefore,
Chinese hospital EMR data provides a unique chance to
conduct the comparison study of different risk adjust-
ment methods in the content of liver disease.
To the best of our knowledge, this is the first study
that compares the performance of common risk adjust-
ment models in predicting in-hospital mortality for the
same large inpatient population with cirrhosis.
Methods
Data source and study population
The data used in our study was derived from the EMR
of Beijing YouAn hospital, one of the leading teaching
hospitals specialized in liver diseases in China and treat-
ing over 300,000 patients from all over China each year.
In 2008, the EMR system was officially implemented in
YouAn hospital and inpatient documentation completely
switched from paper charts to EMR. For each patient,
the EMR contains a front summary page, as well as sec-
tions with detailed information on admission, discharge,
surgery/procedure, death, laboratory test results, radi-
ology test results, pathology report, physician’s notes,
hospitalization billing records, and electronic prescrip-
tion. Among these sections, laboratory test results, elec-
tronic prescriptions, and billing records are completely
structured without any free text. The front page, admis-
sion and discharge records, and radiology test results,
however, are only semi-structured and contain both
structured drop-down lists and free-text fields. The hos-
pital assigned a unique identification number to each pa-
tient; all sections of EMRs are linked using the
identification number.
The study population included patients with cirrhosis
hospitalized at Beijing YouAn hospital between January
1st, 2010 and September 30th, 2014, who were at least
18 years old and consented to use their EMRs for research
(nearly all patients provided consent), and excluded pa-
tients with missing in-hospital mortality status. We ex-
cluded 145 (1.3%) patients due to missing information on
in-hospital mortality (the missing was likely caused by
physicians’ unintentional incomplete documentation) and
180 (1.6%) patients who underwent liver transplantation,
given this group of patients were much more complicated
in contrast to other patients. In total, 11,122 adult cirrho-
sis patients were analyzed. This study was approved by the
YouAn Hospital Research Board of Ethics and the
Health Research Ethics Board at University of Calgary
(Ethic committee’s reference number: REB14-0815).
Outcome and independent variables
The outcome measure was in-hospital mortality that
was recorded in the EMR. Liver disease variables were
defined using our previously developed and validated
EMR case definitions [30]. The validation study showed
that most of the case definitions had high validity (positive
predictive value over 80%). Using the validated case defini-
tions, we defined the following variables: cirrhosis, PLC,
hepatitis, hepatic encephalopathy (HE) and ascites, as well
as the Charlson and Elixhauser comorbidities at the time
of admission. In addition, the laboratory test results re-
quired to construct the CTP and MELD scores were
directly extracted from the EMR system. These laboratory
test results included the serum level of albumin, total
bilirubin, creatinine, sodium (Na), and the international
normalized ratio of prothrombin time (PT-INR). For in-
patient episode with multiple laboratory tests, results from
the tests conducted at or immediately after admission
were used. Only 232 patients had missing values of one of
above laboratory tests. We assumed these missing values
fell in the normal range at admission. Chart review on 30
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charts randomly selected out of these 232 patients sup-
ported this assumption.
Using EMR data in the latest admission, we defined
in-hospital mortality and the laboratory test results. To
define chronic diseases (e.g., comorbidities) we included
the information in the multiple admissions within 1 year
prior to the latest admission date.
Risk adjustment models
Commonly used variants of CCI [10, 12] were tested: the
all individual comorbidities of CCI (referred to as CCI),
the number of Charlson comorbidities categorized (0, 1, 2,
≥3 comorbidities) (referred to as CCI categorized), the
score of CCI (referred to as CCI score), which is the sum-
mation of the weighted score of each comorbidity, and the
categorized CCI score (0, 1–2, 3–4, ≥5 points) (referred to
as CCI score categorized), (See detailed description of the
tested models in Table 1). For ECI, models using the in-
dividual Elixhauser comorbidities (referred to as ECI),
and the number of Elixhauser comorbidities catego-
rized (0, 1, 2, ≥3 comorbidities) (referred to as ECI
categorized) [11] were tested (Table 1). Both CCI and
ECI contain variables related to liver diseases. We ex-
cluded “mild/moderate to severe liver disease” in CCI
and the “liver disease” in ECI. PLC was excluded from
the variables of “any malignancy”, “metastatic solid
tumor”, and “solid tumor without metastases”.
For MELD, three common variants were tested
(Table 1), including MELD score (referred to as MELD
score) [6], MELD sodium score (referred to as MELDNa
score) [31], and five-variable MELD score (referred to as
5vMELD score) [32]. MELD score = 3.78 × ln[serum total
bilirubin (mg/dL)] + 11.2 × ln[INR] + 9.57 × ln[serum cre-
atinine (mg/dL)] + 6.43) [6]. To avoid scores below 0 in
the logarithm, value less than one is rounded to 1 (e.g.,
for total bilirubin with 0.75, a value of 1.0 is assigned).
MELDNa =MELD score + 1.59 [135 - Na], where Na is
bounded between 120 and 135 mmol/L (Na lower than
the low limit is assigned with a value of 120 mmol/L,
and Na higher than 135 mmol/L is assigned a value of
135 mmol/L) [31]. 5vMELD score =MELDNa + (5.275 ×
[4-albumin]) – (0.136 × MELDNa × [4 - serum albumin]),
where albumin is bounded between 1 and 4 g/dL [32].
Two variants of CTP were tested: CTP classification
(referred to as CTP) and CTP score (referred to as CTP
score) (Table 1). The CTP score is defined by summing
the assigned score for each of the five variables including
HE (absence = 1, slight-medium = 2, and refractory = 3),
ascites (none = 1, mild = 2, and moderate to severe = 3),
total bilirubin (<34 μmol/L = 1, 34–50 μmol/L = 2,
and >50 μmol/L = 3), PT-INR (<1.7 = 1, 1.7–2.3 = 2,
and > 2.3 = 3), and albumin (>3.5 = 1, 2.8–3.5 = 2, and
<2.8 = 3) [5]. Calculating CTP score requires the re-
fined severity of HE and ascites; however, 13.5% pa-
tients had unknown severity of HE, and the patients with
unknown severity of ascites accounted for 52.6%. We ex-
cluded these patients from the CTP score model because
we were not able to calculate CTP score for these patients.
To include the patients with unknown severity of HE or
Table 1 The description of compared models
Method Variants Description
Comorbidity methods CCI CCI Charlson individual comorbidities (binary variables)
CCI categorized number of Charlson comorbidities excluding liver
disease (0, 1, 2, ≥3)
CCI score the score of Charlson comorbidities (weighted score)
CCI score categorized the score of CCI categorized as 0, 1–2, 3–4, ≥5
ECI ECI Elixhauser individual comorbidities (binary variables)
ECI categorized number of Elixhauser comorbidities (0, 1, 2, ≥3)
Liver specific severity methods MELD MELD score calculated by total bilirubin, PT-INR, and creatinine
MELDNa score calculated by MELD score and serum sodium
5vMELD score calculated by MELDNa score and serum albumin
CTP CTP the classification of Child-Turcotte-Pugh (including the individual
binary variables of hepatic encephalopathy, ascites, total bilirubin,
prothrombin time, and albumin)
CTP score calculated by summing the weighted score of each CTP variable
Comorbidity + Liver severity MELDNa score + ECI the score of MELDNa + individual binary variable of Elixhauser
comorbidities
CTP + ECI individual binary variables of CTP + individual binary variable of
Elixhauser comorbidities
CTP Child-Turcotte-Pugh, MELD model for end-stage liver disease, MELDNa MELD sodium, 5vMELD five variable MELD, CCI Charlson comorbidity index, ECI Elixhauser
comorbidity index
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ascites, we also categorized HE and ascites into binary var-
iables (presence or absence) in the CTP classification
model. In addition, we tested risk adjustment models
using combination of CTP, MELDNa scorer and ECI
(Table 1). For these models incorporated both comorbidity
index and liver disease severity score, we tested the inter-
actions between different risk adjustment instruments.
Statistical analysis
Descriptive analysis was conducted and logistic regression
models (as described above) were used to predict in-
hospital mortality. The baseline model consisted of age, sex,
and admission status (urgently or not). Concordance-
statistic (c-statistic) was used to assess the performance of
the risk adjustment models [33, 34]. C-statistic of 0.5 means
that the ability of discrimination of the model is zero; the
discrimination power is regarded as “unacceptable” when c-
statistic range from 0.50 to 0.69; or “acceptable” when c-
statistic range from 0.70 to 0.79; or “good to excellent”
when c-statistic is 0.80 or greater. The 10-fold cross valida-
tion [35] was used to calculate the corrected c-statistics to
adjust for the number of independent variables in the
model considering that c-statistic increases with the
number of independent variables. We also conducted
bootstrapping (1000 samples) and calculated 95% confi-
dence interval for c-statistics (95% CI) for internal vali-
dation of the c-statistic of each model [36].
Probability of death for each patient was calculated by
the logistic regression models; patients were ranked and
allocated to different risk groups based on the predicted
probability of death. The agreement of observed and ex-
pected number of death was assessed. Graphs were plot-
ted to show the expected and observed mortality rates
across the various risk groups.
In addition, similar analyses were conducted using the
subsample of patients with viral hepatitis, alcoholic hepa-
titis, PLC, decompensated cirrhosis, and no-procedure
subgroups (without undergoing hepatectomy, liver trans-
plantations, transcatheter arterial chemoembolization, and
endoscopic treatment). All analyses were performed in
SAS version 9.4 (Cary, NC).
Results
Of 11,121 cirrhotic patients (Table 2), the median age
was 53 (interquartile range: 46–61) years, 69.9% (7773)
were male and 11.0% (1219) patients were admitted
emergently. The common causes for cirrhosis were
hepatitis B (73.1%), alcoholic hepatitis (25.0%), hepatitis C
(8.8%), and fatty liver (4.6%). Of the cirrhosis patients,
3824 (34.4%) had PLC (hepatocellular carcinoma account
for 96.5%); and 5433 (48.9%) patients did not undergo any
major surgeries or procedures (i.e., hepatectomy, liver
transplantation, transcatheter arterial chemoembolization,
sclerotherapy and variceal banding), radiofrequency
ablation or radiotherapy. Overall the in-hospital mortal-
ity was 8.3%.
Outcome measure and independent variables
At time of admission, 25.0% (2764) of the cirrhotic patients
were diagnosed with hyponatremia (Na < 135 mmol/L),
19.7% (2190) with high creatinine level (>88.4 umol/L),
9.5% (1051) with abnormal PT-INR (>1.7), 40.98% (4558)
with high total bilirubin level (>34.2 umol/L), and 51.7%
(5752) with hypoproteinemia (albumin < 2.8 g/dL). At time
of admission, 18.6% (2069) of the cirrhotic patients had HE,
and 58.3% (6478) had ascites. The most common five co-
morbidities were diabetes uncomplicated (35.6%), hyperten-
sion (complicated and uncomplicated) (28.5%), alcohol
abuse (25.0%), fluid and electrolyte disorder (15.4%) and
peptic ulcer disease (11.1%).
In general, in-hospital mortality was higher among
male patients, older patients, urgently admitted patients,
patients with abnormal clinical variables, patients with a
certain comorbidity (except for acquired immune defi-
ciency syndrome and peripheral vascular disease), or pa-
tients with higher MELD, MELDNa or 5vMELD score
than their counterparts (see Table 3). As number of
Charlson or Elixhauser comorbitites increased, so did in-
hospital mortality. A similar pattern was found with the
number of abnormal CTP variables.
Performance of risk adjustment models
The c-statistics and its 95% confidence intervals (CI) of
the risk adjustment models predicting in-hospital mor-
tality for overall cirrhotic patients were presented in
Table 4, while those for the subgroups of cirrhotic pa-
tients (viral hepatitis, alcoholic hepatitis, PLC, decom-
pensated cirrhosis, and non-procedure) were presented
in Table 5.
For model with age, sex and admission status as the
baseline model, c-statistic was 0.628 (95% CI: 0.609–0.650).
All risk adjustment models with comorbidities, MELD or
CTP significantly outperformed the baseline model, with
c-statistics ranging from 0.785 to 0.887. For models with
variable of the number of comorbidities (0, 1, 2 and ≥3),
the c-statistic obviously dropped from 0.825 (95% CI:
0.749–0.848) to 0.794 (95% CI: 0.743–0.841) for ECI;
and from 0.809 (95% CI: 0.792–0.822) to 0.786 (95% CI:
0.771–0.801) for CCI. The CCI score categorized model
had very similar c-statistic with the CCI score model
(0.786 versus 0.785). The c-statistic for MELD score
model (0.818, 95% CI: 0.805–0.833) was significantly
lower than MELDNa score model (0.849, 95% CI:
0.838–0.861) and 5vMELD score model (0.845, 95% CI:
0.833–0.858). The performance of the CTP is very simi-
lar with the MELDNa score (c-statistics 0.851 versus
0.849, p = 0.073). The performance of CTP score was
significantly lower than CTP (c-statistics: 0.793, 95%
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Table 2 Characteristics of patients with cirrhosis (N = 11,121)
Characteristics Median (interquartile range)
or frequency
Na (mmol/L) 138.4 (135.0–140.0)
Creatinine (umol/L) 66.3 (54.5–81.9)
PT-INR 1.2 (1.0–1.4)
Total bilirubin (umol/L) 27.2 (17.1–59.3)
Albumin (g/dl) 34.7 (29.4–40.0)
CTP scorea 5.0 (5.0–6.0)
MELD score 8.0 (7.0–11.0)
MELDNa score 10.0 (8.0–14.0)
5vMELD score 13.0 (9.0–18.0)
Charlson comorbidity score 1 (0–2)




≥ 65 1761 (15.8%)
Male 7773 (69.9%)
Urgent admission 1219 (11.0%)
Na < 135 mmol/L 2764 (24.9%)
Creatinine > 88.4 umol/L 2190 (19.7%)
PT-INR
< 1.7 (normal range) 10071 (90.6%)
1.7–2.2 724 (6.5%)
> 2.2 327 (2.9%)
Total bilirubin (umol/L)
< 34.2 (normal range) 6564 (59.0%)
34.2–51.3 1328 (11.9%)
> 51.3 3230 (29.0%)
Albumin (g/dl)
> 3.5 (normal range) 5370 (48.3%)
2.8–3.5 3660 (32.9%)
< 2.8 2092 (18.8%)
Hepatic encephalopathyb
Grade I-II 455 (4.1%)
Grade III-IV (or refractory) 109 (1.0%)
Severity unknown 1505 (13.5%)
Ascitesb
Mild 522 (4.7%)
Moderate to sever 103 (0.9%)
Severity unknown 5853 (52.6%)
CTP classificationb
A (CTP score 5–6) 3952 (35.5%)
B (CTP score 7–9) 1002 (9.0%)
C (CTP score 10–15) 80 (0.7%)
Table 2 Characteristics of patients with cirrhosis (N = 11,121)
(Continued)




≥ 3 3674 (33.0%)




≥ 3 766 (6.9%)




≥ 3 2933 (26.4%)
Charlson comorbidities
Myocardial infarction 62 (0.6%)
Cerebrovascular disease 371 (3.3%)
Dementia 6 (0.1%)
Renal disease 1228 (11.0%)
Any malignancyc 645 (5.8%)
Charlson and Elixhauser shared comorbidities
Congestive heart failure 25 (0.2%)
Peripheral vascular disease 7 (0.1%)
Chronic pulmonary disease 191 (1.7%)
Rheumatologic disease 62 (0.6%)
Peptic ulcer disease 1234 (11.1%)
Diabetes complicated 130 (1.2%)
Diabetes uncomplicated 3957 (35.6%)
Hemiplegia or paraplegia 8 (0.1%)
Metastatic solid tumorc 275 (2.5%)
AIDS 40 (0.4%)
Elixhauser comorbiditiesd
Cardiac arrhythmias 447 (4.0%)
Valvular disease 30 (0.3%)
Hypertension uncomplicated 2008 (18.1%)
Hypertension complicated 1156 (10.4%)
Hypothyroidism 95 (0.9%)
Lymphoma 20 (0.2%)
Solid tumor without metastasisc 178 (1.6%)
Coagulopathy 5 (0.04%)
Blood loss anemia 335 (3.0%)
Deficiency anemia 959 (8.6%)
Depression 41 (0.4%)
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CI: 0.736–0.844 versus 0.851, 95% CI: 0.839–0.864). In
summary, for the overall cirrhotic patients, among the
risk adjustment models, c-statistics increased in a con-
sistent order from the CCI, ECI, MELDNa score, to
CTP. The comparison result using bias-corrected c-
statistic was slightly different (order from low to high
performance: CCI, ECI, CTP to MELDNa score). The
corrected c-statistics for CTP and MELDNa score
models were very similar (0.847 versus 0.849).
Results on model performance within patient’s sub-
groups (those with viral hepatitis, alcoholic hepatitis,
PLC, decompensated cirrhosis, and no-procedure sub-
groups) remained the same: c-statistics increased in a
consistent order from the CCI, ECI to MELDNa score
(or CTP). Compared with models employing only single
risk adjustment model, c-statistic of models that com-
bined both liver disease severity and comorbidity indexes
was shown to be better. Model combining CTP and ECI
improved the c-statistic compared with the CTP model
(c-statistics: 0.887 versus 0.851, p < 0.0001). Similarly,
model that combined ECI and MELDNa score outper-
formed model that includd MELDNa score only (c-sta-
tistics: 0.882 versus 0.849, p < 0.0001).
Figure 1 presents the observed and expected mortality
across model-defined risk groups for the six models
(CCI, ECI, MELDNa score, CTP, ECI +MELDNa score,
and ECI + CTP) in the overall sample. The “spread-out”
of the expected mortality generated from combined
models (i.e., CI +MELDNa score and ECI + CTP) was
much wider than the models with only comorbidities,
MELD or CTP.
Discussion
To the best of our knowledge, this is the first study that
compared the performance of common risk adjustment
methods in predicting in-hospital mortality for patients
with cirrhosis, using large Chinese EMR data. The EMR
data provided comprehensive information on both
comorbidities as well as disease specific clinical informa-
tion for large inpatient sample, presenting researchers a
valuable opportunity to assess performance of various
risk adjustment models on the same patient population.
Our large sample also statistically empowered precision
of the assessment. Overall, our study highlighted: 1) liver
specific scores of CTP and MELDNa performed better
than comorbidity methods of CCI and ECI; 2) combin-
ation of liver disease severity and comorbidity indexes
(such as CTP + ECI or MELDNa score + ECI) signifi-
cantly improved performance of in-hospital mortality
prediction; and 3) these findings were consistent across
subtypes of liver diseases.
Comparison of risk adjustment methods
We assessed the performance of risk adjustment
models in predicting in-hospital mortality for patients
with cirrhosis, using a single model or a combination of
two models among ECI and CTP (or MELDNa score).
All models significantly outperformed the baseline
model with age, sex, and admission status. These re-
sults provided support of the use of these models as
risk adjustment instruments for liver disease. While all
models were shown to have reasonable predictive power,
liver disease severity indexes (CTP and MELDNa score)
were shown to be better than the comorbidity indexes
(CCI and ECI). Moreover, comparing with individual co-
morbidity or liver disease severity index, combined models
(e.g., CTP + ECI or MELDNa + ECI) demonstrated higher
performance in predicting in-hospital mortality.
Between the two comorbidity indexes tested, ECI was
found to be more predictive than CCI among all cir-
rhotic patients as well as for all the subgroups. This re-
sult was consistent with findings in the existing risk
adjustment literatures for liver disease that used admin-
istrative data [9, 16, 18, 37]. The better performance of
ECI could be explained by that ECI identified substan-
tially more conditions than CCI, which contributed to a
higher c-statistic [16, 37]. In our study, we used a cate-
gory of number of comorbidities presence as one inde-
pendent variable for ECI and CCI. This method showed
similar c-statistics for ECI and CCI (0.794 versus 0.786).
Among the liver disease severity indexes tested, the
discrimination ability of CTP was consistently shown to
be higher than MELD and 5vMELD scores, and close to
MELDNa score among all of the subgroups. This proved
the appropriateness of ongoing use of CTP in practice to
predict in-hospital mortality in cirrhotic patients. How-
ever, refined degree of HE and ascites may not be avail-
able in many datasets, making it impossible to use CTP
as a risk adjustment instrument. The construction of
MELDNa score only requires routine laboratory test re-
sults, which makes MELDNa score more reproducible,
reliable and easier to apply [20–22]. More importantly,
Table 2 Characteristics of patients with cirrhosis (N = 11,121)
(Continued)
Fluid and electrolyte disorders 1707 (15.4%)
Alcohol abuse 2780 (25.0%)
Psychoses 19 (0.2%)
Renal failure 236 (2.1%)
IQR interquartile range, Na serum sodium, PT-INR international normalized
ratio of prothrombin time, LOS length of stay in hospital, CTP Child-Turcotte-
Pugh, MELD model for end-stage liver disease, MELDNa MELD sodium, 5vMELD
five variable MELD, AIDS acquired immune deficiency syndrome
aCTP score was not available for patients with unknown severity of HE or ascites
bThe sum of proportion of the categories is less than 100% because there
were missing values on acsites and hepatic encephalopathy
cExcluded primary liver cancer
dThe obesity, weight loss, pulmonary circulatory disorders, other neurological
disorders and drug abuse were excluded due to 0% prevalence
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Age (year) 18–44 4.9 (125) <0.0001
45–64 8.0 (543)
≥65 14.3 (252)
Sex male 9.1 (704) <0.0001
female 6.5 (216)
Admission status non-urgent 6.3 (627) <0.0001
urgent 24.0 (293)
Hepatic encephalopathy no 4.0 (360) <0.0001
yes 27.1 (560)
Ascites no 1.8 (85) <0.0001
yes 12.9 (835)
PT-INR <1.7 6.2 (628) <0.0001
1.7–2.3 23.2 (168)
>2.3 37.9 (124)
Total bilirubin (umol/L) <34.2 4.1 (271) <0.0001
34.2–51.3 7.1 (94)
>51.3 17.2 (555)
Albumin (g/dl) >35 3.2 (170) <0.0001
28–35 10.0 (367)
<28 18.3 (383)
Creatinine (umol/L) ≤88.4 5.0 (445) <0.0001
>88.4 21.7 (475)
Na ≥135 4.4 (364) <0.0001
<135 20.1 (556)












CTP classification A (CTP score 5–6) 0.9 (34) <0.0001
B (CTP score 7–9) 3.2 (32)
C (CTP score 10–15) 11.3 (9)
Number of abnormal
CTP variables




Table 3 Crude in-hospital mortality by study variables (N= 11,121)
(Continued)
Myocardial infarction no 8.2 (902) <0.0001
yes 29.0 (18)
Cerebrovascular disease no 7.9 (846) <0.0001
yes 20.0 (74)
Renal disease no 5.9 (586) <0.0001
yes 27.2 (334)
Any malignancya no 8.0 (841) <0.0001
yes 12.2 (79)
Congestive heart failure no 8.3 (10) <0.0001
yes 40.0 (10)
Chronic pulmonary disease no 8.1 (888) <0.0001
yes 16.8 (32)
Rheumatologic disease no 8.3 (913) 0.39
yes 11.3 (7)
Peptic ulcer disease no 8.1 (801) 0.06
yes 9.6 (119)
Diabetes complicated no 8.3 (907) 0.47
yes 10.0 (13)
Diabetes uncomplicated no 5.2 (374) <0.0001
yes 13.8 (546)
Hemiplegia or paraplegia no 8.3 (919) 0.66
yes 12.5 (1)
Metastatic solid tumor no 7.8 (844) <0.0001
yes 27.6 (76)
Cardiac arrhythmias no 7.9 (840) <0.0001
yes 17.9 (80)
Valvular disease no 8.3 (916) 0.31
yes 13.3 (4)
Hypertension uncomplicated no 7.8 (708) <0.0001
yes 10.6 (212)
Hypertension complicated no 7.9 (784) <0.0001
yes 11.8 (136)
Hypothyroidism no 8.3 (911) 0.67
yes 9.5 (9)




no 8.1 (886) 0.31
yes 19.2 (34)
Coagulopathy no 8.3 (918) 0.01
yes 40.0 (2)
Blood loss anemia no 7.6 (818) <0.0001
yes 30.5 (102)
Deficiency anemia no 7.4 (755) <0.0001
yes 17.2 (165)
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our results showed that the performance of MELDNa
score were very close to or better than that of CTP. This
indicates that using MELDNa score instead of CTP
might simplify the analysis without compromising the
predictive accuracy.
MELDNa and 5vMELD scores had similar perform-
ance in predicting in-hospital mortality. 5vMELD score
was generated through adding serum albumin level to
MELDNa score. The additional variable in 5vMELD did
not significantly improve its predictability of in-hospital
mortality. The possible reason is that albumin level
Table 3 Crude in-hospital mortality by study variables (N= 11,121)
(Continued)




no 5.5 (519) <0.0001
yes 23.5 (401)
Psychoses no 8.3 (918) 0.72
yes 10.5 (2)
Renal failure no 7.4 (803) <0.0001
yes 49.6 (117)
AIDS no 8.3 (920) 0.06
yes 0.0 (0)
Peripheral vascular disease no 8.3 (920) 0.43
yes 0.0 (0)




















IQR interquartile range, Na serum sodium, PT-INR International normalized
ratio of prothrombin time, CTP Child-Turcotte-Pugh, MELD model for end-stage
liver disease, MELDNa MELD sodium, 5vMELD five variable MELD, AIDS acquired
immune deficiency syndrome
1P-value of Chi-square exact test is for each contingency table (mortality by
each predictor)
aExcluded primary liver cancer
Table 4 C-statistics (95% CI) for predicting in-hospital mortality
of the compared risk adjustment methodsa in the overall cirrhosis





CCI 0.809 (0.792–0.822) 0.816
CCI categorized 0.786 (0.771–0.801) 0.784
CCI score 0.785 (0.769–0.799) 0.787
CCI score categorized 0.786 (0.770–0.801) 0.783
ECI 0.825 (0.749–0.848) 0.827
ECI categorized 0.794 (0.743–0.841) 0.773
MELDNa score 0.849 (0.838–0.861) 0.849
5vMELD score 0.845 (0.833–0.858) 0.847
MELD score 0.818 (0.805–0.833) 0.817
CTP 0.851 (0.839–0.864) 0.847
CTP score 0.793 (0.736–0.844) 0.803
MELDNa score + ECI 0.882 (0.826–0.898) 0.882
CTP + ECI 0.887 (0.846–0.901) 0.885
CI confidence interval, CCI Charlson comorbidity index, ECI Elixhauser comorbidity
index, CTP Child-Turcotte-Pugh, MELD model for end-stage liver disease, MELDNa
MELD sodium, 5vMELD five variable MELD
aAge, sex and admission status were included in all regression models
b1000 samples bootstrapping mean c-statistic and 95% CI
c10-fold cross validation corrected c-statistic
Table 5 C-statistics (95% CI)a of the logistic regression modelsb in the subgroups of cirrhotic patients
Model Viral hepatitis PLC Alcoholic hepatitis Decompensated No-procedurec
Number of cases (%) 8132 (73.1) 3824 (34.4) 2778 (25.0) 7183 (64.6) 5433 (48.9)
CCI 0.807 (0.789–0.825) 0.788 (0.764–0.812) 0.791 (0.761–0.817) 0.788 (0.771–0.805) 0.796 (0.778–0.815)
ECI 0.821 (0.756–0.846) 0.828 (0.805–0.849) 0.837 (0.809–0.860) 0.807 (0.786–0.825) 0.834 (0.817–0.852)
MELDNa score 0.848 (0.835–0.863) 0.846 (0.828–0.861) 0.853 (0.833–0.873) 0.827 (0.810–0.841) 0.845 (0.831–0.860)
CTP 0.856 (0.842–0.869) 0.869 (0.851–0.885) 0.847 (0.827–0.867) 0.822 (0.806–0.838) 0.852 (0.837–0.867)
MELDNa score + ECI 0.878 (0.836–0.897) 0.888 (0.871–0.903) 0.896 (0.876–0.914) 0.863 (0.846–0.877) 0.889 (0.876–0.902)
CTP + ECI 0.887 (0.847–0.905) 0.907 (0.891–0.920) 0.897 (0.878–0.914) 0.864 (0.848–0.877) 0.892 (0.878–0.904)
CI confidence interval, CCI Charlson comorbidity index, ECI Elixhauser comorbidity index
CTP Child-Turcotte-Pugh, MELDNa model for end-stage liver disease and sodium
a1000 samples bootstrapping mean c-statistic and 95% CI
bAge, sex and admission status were included in all regression models
cProcedure refers to the major procedures such as the hepatectomy, liver transplantation, transcatheter arterial chemoembolization, endoscopic treatment
(i.e., sclerotherapy and variceal banding), and radiofrequency ablation and radiotherapy
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Fig. 1 Expected and observed mortality in various risk groups for patients with cirrhosis. CTP: Child-Turcotte-Pugh; MELDNa: model for end-stage
liver disease and sodium
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measured during hospitalization did not reflect the
patient’s severity of disease because albumin was
commonly administrated in inpatients with cirrhosis.
Overall, the liver disease severity indexes (MELD
score and CTP) outperformed the comorbidity indexes
(CCI and ECI) on prediction of in-hospital mortality.
The possible reason is that the most recent laboratory test
results within one hospitalization episode could reflect the
severity of liver disease at the occurrence of hospitalization
outcome (mortality). We conducted sensitivity analysis to
address this explanation. We calculated MELDNa score at
near discharge time and fitted model to predict in-hospital
mortality. The c-statistic for MELDNa model increased
significantly from 0.849 (95% CI: 0.838–0.861) for near
admission time to 0.912 (95% CI: 0.903–0.921) for near
discharge time. This supported our hypothesis that the
performance of risk adjustment instruments improves
when they are constructed based on information collected
close to the outcome event.
The model incorporated MELDNa score and Elixhauser
comorbidities obtained significantly higher predictive ability
compared to the MELDNa score model. This indicated that
to increase predictive probability of mortality during
hospitalization, physicians should not only consider the
MELDNa score but also presence of comorbidities. Further
research is required to develop summary score and cut-off
value to predict individual patient’s outcome.
Limitations
Our study has several limitations. First, we used data de-
rived from one hospital EMRs, and the generalizablility
of the results may be a concern. However, generally the
c-statistics of the compared risk adjustment methods
were consistent with results from other studies in exist-
ing literatures [9–12, 15, 20–23]. Second, we only ana-
lyzed inpatient EMR data and were unable to assess
patients’ outcome after discharge. Third, the odds ratios
of certain predictors were not reliable due to low preva-
lence. The possible reason for the low prevalence of
these diseases is that the data is from a hospital specialized
in liver disease. However, the purpose of this study is to
compare the performance of the common risk adjustment
instruments. Lastly, the missing values on certain variables
were common. In our EMRs, presence of ascites was well
recorded but degree of ascites was often missing (more
than 50%). Exclusion of these patients from the CTP score
model could under-estimate the c-statistic. Other study
also reported that severity of HE and ascites was com-
monly missing [22].
Conclusion
The liver specific scoring instruments of CTP and
MELDNa outperformed the ECI and CCI methods for
predicting in-hospital mortality among patients with
cirrhosis using Chinese EMRs. Combining severity and
comorbidities could improve the statistical power of
predicting in-hospital mortality. These risk adjustment
methods should be further evaluated for predicting
long-term outcomes.
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